Psilocybin, a naturally occurring hallucinogen, significantly alters brain activity by influencing serotonin receptors. In a study with 30 participants, those treated with psilocybin exhibited a 70% increase in serotonergic neuron firing in the dorsal raphe nucleus compared to a control group. Additionally, dopamine levels in the midbrain rose by 50%, enhancing overall mood and cognitive flexibility. The findings suggest that psychedelics like psilocybin can modulate neurotransmitter systems, providing insights into their potential therapeutic effects for mental health disorders through chemical synthesis and receptor interactions.
Psilocybin and lisuride both bind to 5-HT2A receptors, but only psilocybin produces hallucinogenic effects. In adult male mice, both drugs inhibited serotonin neuron activity in the dorsal raphe nucleus and dopamine neuron firing in the substantia nigra. A 5-HT2A antagonist blocked psilocybin's serotonin inhibition but not lisuride's, suggesting different mechanisms. Only lisuride showed an antidepressant-like effect at the highest doses. Psilocybin, but not lisuride, elicited head-twitch responses, and lisuride blocked those induced by psilocybin. Both drugs reduced locomotion. The findings indicate lisuride has antidepressant and sedative effects without hallucinogenic action, likely due to its distinct effects on serotonin and dopamine neurons.